SC-67655, Agonist of death receptor 4, CAS No.rp174953, Agonist of death receptor 4

CAS: rp174953 Cat. No.: rp174953
Disponibile su ordine
QUALITÀ & PUREZZA Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
★
Dimensione
Germania (EU)
USA*
Prezzo
Qtà
500μg
rp174953-500μg
Su ordinazione · 8–12 settimane
2.082,49€
1mg
rp174953-1mg
Su ordinazione · 8–12 settimane
3.470,87€
Enter a quantity for the sizes you want to add.

Specifiche

Product Name
SC-67655, Agonist of death receptor 4, CAS No.rp174953
Grado
Moligand™
Specifiche e purezza
Moligand™
Tipo di azione
AGONIST
Meccanismo d'azione
Agonist of death receptor 4
CAS
rp174953
Tipo di molecola
Peptidi
Product Line
Prodotti biologici
Stoccaggio e spedizione
Condizioni di conservazione di stoccaggio
Room temperature

Dati avanzati

Obiettivi associati (umani)
TNFRSF10A Tchem Tumor necrosis factor receptor superfamily member 10A (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Informazioni genetiche
Reference
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Application Protocols

No validated, item-specific application protocols are provided for SC-67655. The following generic procedures reflect common handling of small-molecule screening compounds.

Preparing a DMSO stock (general):

  • Determine molecular weight from the CoA. For a 10 mM solution: weigh mass (mg) = 10 × MW × volume (mL) / 1000. Dissolve in anhydrous DMSO, vortex 30–60 s, and sonicate briefly if needed. Inspect for clarity and absence of particulates.

Plate formatting for HTS (general):

  • Aliquot stocks into solvent-compatible plates or tubes under dry conditions. Seal with DMSO-resistant films. Minimize headspace to limit water uptake. Record plate maps and barcodes.

Assay dilution (general):

  • Dilute into assay buffer to the desired test concentrations, maintaining constant vehicle (e.g., 0.1–1% DMSO) in all wells including controls. Mix gently to avoid foaming; incubate per assay requirements.

Controls and QC (general):

  • Include positive/negative controls, vehicle controls, and counter-screens to identify interference. Confirm concentration by UV (if chromophore present) or LC–MS where feasible.

Note: Adjust these steps to your platform and to any item-specific solubility/stability information in the CoA.

Biological Roles

No biological function, pathway involvement, or target annotations are provided for SC-67655.

General guidance for screening compounds (not specific to this item):

  • Until a target and mechanism are established by your assays, treat the compound as an uncharacterized chemical probe. Avoid biological inferences without orthogonal evidence.
  • Assess potential liabilities common to screening collections: pan-assay interference compounds (PAINS), redox cyclers, aggregators, covalent promiscuity, fluorescence/absorbance interference, or metal chelation. Use orthogonal assay formats and counter-screens to differentiate true activity from artifacts.
  • If activity is observed, prioritize mode-of-action studies: concentration–response curves across assay formats, time-dependence, reversibility tests, and control experiments varying detergent and protein concentration to identify nonspecific behavior.

Note: This product is for research use only. No medical, diagnostic, or therapeutic claims are made or implied.

Buffer Applications

This product is a small-molecule screening compound and is not a buffering agent. Therefore, conventional buffer system design (e.g., phosphate, HEPES, Tris) is not directly applicable.

Practical notes for assay buffers (general guidance):

  • Maintain a constant vehicle percentage (e.g., 0.1–1% DMSO) across control and treated wells to avoid solvent-related artifacts.
  • Select buffers with minimal UV/fluorescence background when using optical readouts; match pH and ionic strength to the biological system.
  • Consider adding 0.01–0.05% nonionic surfactant (e.g., polysorbate 80) to mitigate colloidal aggregation if compatible with the assay.

Item-specific buffer compatibility for SC-67655 is not specified; consult your internal assay validation data.

Green Alternatives

Because structure and solubility are not disclosed, solvent selection must balance assay performance, safety, and environmental impact (general guidance):

Greener vehicles for stock or working solutions (literature/general):

  • Ethanol (EtOH): Biorenewable routes available; lower toxicity profile than dipolar aprotics. Limited solvency vs DMSO; volatility can alter concentrations in open systems.
  • 2-Propanol (IPA): Widely available, lower toxicity; moderate solvency; often tolerated up to ~1% v/v in biochemical assays.
  • PEG-400 or glycerol: Low volatility, useful as co-solvents; can increase viscosity and complicate automation.

Comparison (general; not item-specific):

  • DMSO: Excellent solvency and chemical stability; environmental and worker-exposure considerations; typically required for challenging chemotypes.
  • EtOH/IPA: Greener but may not dissolve highly lipophilic compounds at millimolar levels.
  • Aqueous buffers at adjusted pH: Greenest option if the compound is ionizable and stable; verify target compatibility.

Practical approach:

  • Start with the lowest-impact solvent compatible with your assay and the compound’s solubility. Escalate to DMSO or NMP only if needed.
  • Use minimal organic percentage in assay wells (e.g., ≤1% v/v) to reduce environmental burden and biological artifacts.
  • Implement solvent recycling where feasible and capture organic waste streams for appropriate disposal.
Pharmaceutical Uses

SC-67655 is supplied for research use only and is not intended for human or veterinary use, clinical diagnostics, or as an excipient.

Context for formulation scientists (general, non-clinical):

  • Early discovery compounds may be evaluated in pre-formulation screens to understand solubility, stability, and compatibility with common excipients. No such data are provided for this item.
  • If conducting non-clinical formulation feasibility studies, determine: solid form (polymorph/salt), hygroscopicity, pKa/logD (to guide salt selection), and chemical stability in candidate vehicles. None of these parameters are specified here for SC-67655.

Pharmacopeial status: Not specified for this item; refer to CoA/Spec Sheet.

No claims are made regarding therapeutic indications, ADME, or safety; this listing pertains solely to laboratory research.

Physical Properties

Item-specific physicochemical data have not been disclosed for SC-67655.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point / boiling point: Not specified for this item; refer to CoA/Spec Sheet.
  • Density, refractive index: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • logP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule screening compounds (literature/general):

  • Stock solutions are commonly prepared at 10–50 mM in anhydrous DMSO due to broad solvating power for drug-like molecules.
  • Where aqueous work is required, co-solvent strategies (e.g., DMSO 1–5% v/v in buffer) or cosolvent + surfactant (e.g., 0.01–0.05% Tween-80) may aid dissolution while minimizing assay interference.
  • If the compound is ionizable, aqueous solubility can vary strongly with pH; Henderson–Hasselbalch analysis can guide pH adjustments once pKa values are known.

Please consult the CoA/Spec Sheet for the definitive, item-specific physical properties of SC-67655.

Quality and Grades
  • Grade/Purity designation: Moligand™ (as listed for this item). Specific numeric purity or stabilizers: Not specified for this item; refer to CoA/Spec Sheet.

About Moligand™ (general description; not item-specific specifications):

  • Moligand™ designates small-molecule library members intended for discovery workflows (e.g., HTS, fragment-based screening, or secondary assays). The emphasis is typically on confirmed identity and assay-ready handling characteristics rather than application in regulated environments.
  • Typical expectations for screening compounds include structure confirmation and chromatographic purity suitable for screening. However, for SC-67655, exact analytical methods, purity thresholds, residual solvent/metal levels, and UV cutoffs are not specified here.

What to request for this item:

  • Certificate of Analysis (CoA) with structure depiction (SMILES/SDF), measured purity (e.g., LC–UV/ELSD), identity confirmation (LC–MS/HRMS, 1H NMR), water content (if relevant), and storage guidance.
  • If your workflow is LC–MS–sensitive, request detailed method parameters and chromatograms to assess potential assay interferences.

Fit for purpose guidance:

  • For HTS or profiling, verify solubility at the intended stock concentration (commonly 10 mM in DMSO) and confirm compatibility with your assay buffer system.
  • For structure–activity work, align on consistent analytical methods across batches to ensure comparability.
Reaction and Applications

SC-67655 is offered as a Moligand™ small molecule for research use. Without structural disclosure, synthetic reaction planning is not applicable. Instead, consider its roles in discovery workflows (general guidance):

  • Primary applications: High-throughput screening (HTS), hit triage, orthogonal assay confirmation, and early structure–activity relationship (SAR) exploration once the structure is available.
  • Profiling: Use counter-screens to de-risk nuisance behaviors (aggregation, redox cycling, assay interference). Include solubility/colloidal checks (e.g., light scattering, detergent sensitivity) during hit validation.
  • Biophysical follow-up: If a biophysical platform is used (DSF, MST, SPR, NMR), confirm sample homogeneity and absence of visible particulates; match buffer composition across reference and analyte channels.
  • Chemical stability: In the absence of specific data, test stability in assay media and DMSO over relevant timeframes (e.g., 24–72 h at room temperature or 4°C). Monitor by LC–MS for degradation or adduct formation (e.g., with buffer components).
  • Plate handling: Minimize freeze–thaw and headspace to limit DMSO uptake of water. Use plate seals rated for organic solvents. Track plate-map metadata for reproducibility.

Note: For any synthetic derivatization or analog preparation, obtain the structure and analytical package from the CoA and plan routes accordingly.

Reaction Conditions

Reaction condition guidance is not applicable without knowledge of SC-67655’s functional groups and reactivity profile.

General discovery support (literature/general):

  • For analog synthesis following hit validation, typical conditions may involve: Pd-catalyzed cross-couplings (Suzuki–Miyaura, Buchwald–Hartwig), modern amide couplings (e.g., HATU, EDCI), or heterocycle formations under microwave assistance. Choose solvents and bases guided by the specific coupling partners.
  • Characterize intermediates and final products by LC–MS and NMR; establish a stability-indicating assay for storage and shipping.

Item-specific reaction parameters, catalysts, and yields: Not specified for this item; refer to CoA/Spec Sheet once the structure is disclosed.

Safety and Handling

Hazard information for SC-67655 has not been provided in this listing. Always consult the SDS for authoritative guidance before use.

  • GHS signal word, hazard statements, pictograms: Not specified for this item; refer to SDS.
  • Primary hazards: Unknown. Handle as a potentially harmful laboratory chemical.

General laboratory precautions (good practice):

  • Wear appropriate PPE: lab coat, safety glasses, and suitable chemically resistant gloves (e.g., nitrile). Work in a chemical fume hood to avoid inhalation of dusts or vapors.
  • Avoid ingestion, inhalation, and skin/eye contact. Prevent aerosol/dust generation during weighing or dispensing.
  • Incompatibilities: Unknown; keep away from strong oxidizers, strong acids/bases, and ignition sources until specific data are known.
  • First aid (overview; defer to SDS): If inhaled—move to fresh air; if on skin—wash with soap and water; if in eyes—rinse cautiously with water for several minutes; if ingested—rinse mouth. Seek medical attention if symptoms persist.
  • Spill response: Absorb small spills with inert material (vermiculite, sand), collect in a chemical waste container. Decontaminate surfaces with suitable solvent/detergent per institutional procedures.
  • Waste disposal: Dispose of in accordance with local regulations and your institution’s hazardous waste policies.

Note: No claims are made regarding environmental fate, sensitization, mutagenicity, or other endpoints; refer to the SDS for SC-67655 when available.

Solvent Selection

Item-specific solubility data are not available for SC-67655. The following guidance reflects common practice for small-molecule screening compounds (literature/general):

  • Primary solvent for stocks: Anhydrous DMSO (high polarity aprotic, dielectric constant ~47 at 20–25°C; literature) due to broad solubilization of drug-like scaffolds and stability in sealed microplates.
  • Alternative vehicles for difficult solutes: NMP, DMF (strong dipolar aprotics), or co-solvent systems (e.g., 10–30% DMSO in water, or ethanol/water). Balance solvent strength with assay tolerance and potential target interference.
  • Aqueous systems: For ionizable compounds, adjust pH to favor the ionized form (bases in mildly acidic buffers, acids in mildly basic buffers) to increase kinetic solubility. Verify assay compatibility.
  • Surfactant-assisted dissolution: Low levels of nonionic surfactants (e.g., 0.01–0.05% polysorbate 80) can mitigate aggregation; confirm they do not affect readouts.

Quick comparison (literature/general):

  • DMSO: Widest solubility window; broadly assay-compatible at ≤1–2% v/v.
  • Ethanol: Volatile; often tolerated up to ~1% v/v; may perturb membranes/enzymes.
  • PEG-400: Low volatility; enhances solubility but increases viscosity; may affect HTS dispensing.

Recommendation: Begin with a 10 mM DMSO stock, verify clarity after 10–15 min at room temperature, then perform serial dilutions into assay buffer maintaining constant vehicle percentage.

Storage and Reconstitution
  • Storage conditions (as provided): Room temperature for the supplied form. Protect from moisture, heat, and light until more specific guidance is available from the CoA/SDS.
  • Shipped in: Not specified for this item; refer to CoA/Spec Sheet.

General best practices for screening compounds (solid):

  • Store tightly sealed in a desiccator or low-humidity environment at ambient temperature per listing. Record receipt date and any observed appearance.

Reconstitution (general):

  • Prepare concentrated stocks in anhydrous DMSO (commonly 10–50 mM) once molecular weight is known. Filter through a PTFE membrane (0.2 µm) only if compatible and if particulate is observed; avoid adsorption losses for low-mass samples.
  • Aliquot stocks into single-use or limited-use portions to minimize freeze–thaw.

Storage of solutions (general):

  • DMSO stocks are commonly stored at −20 to −80°C in tightly sealed vials/plates with solvent-resistant seals. Avoid repeated freeze–thaw; thaw at room temperature and mix thoroughly before use. Track cumulative freeze–thaw cycles.

Stability and shelf life:

  • Not specified for this item; refer to CoA/Spec Sheet. Verify stability by periodic LC–MS or LC–UV checks, especially for long-term studies.
Structure and Identity

This listing (SC-67655; SKU rp174953) is supplied as a Moligand™ small-molecule library member intended for research screening and discovery.

  • Chemical name: Not specified for this item; refer to CoA/Spec Sheet.
  • CAS: rp174953 (catalog placeholder; not a standard CAS RN)
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChI / InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general guidance for Moligand™ library members; not item-specific):

  • May encompass diverse chemotypes (heteroaromatics, privileged scaffolds, sp3-rich motifs, or fragment-like cores) designed for broad target coverage. Exact functional groups, stereochemistry, and ring systems for SC-67655 are not provided here.

2D description (item-specific):

  • Not available. Request the structure file (SDF/MOL) and analytical identifiers from the Certificate of Analysis (CoA) or product Spec Sheet for unambiguous confirmation.

Identity confirmation (typical practices for screening compounds; literature/general):

  • Common confirmation methods include LC–MS, 1H NMR, and HRMS. Specific datasets for SC-67655 are not provided; consult the CoA.
Synthetic Utility

Without a disclosed structure, detailed synthetic transformations, reactivity, and retrosynthetic roles cannot be provided for SC-67655.

General considerations for similar small molecules (literature/general):

  • If the scaffold is later revealed, retrosynthetic analysis should identify robust disconnections (e.g., cross-coupling, amide bond formation, heteroaryl construction, C–H functionalization) that enable analog generation for SAR.
  • Functional group compatibility and protecting-group strategy must be tailored to the specific chemotype; employ convergent routes where possible to accelerate library expansion.

Action items:

  • Request the structure (SDF/MOL) and any synthetic route notes from the CoA to plan analog synthesis or scale-up.
  • Verify stereochemical assignments and enantiopurity if chirality is present; confirm by chiral HPLC or VCD as needed.
Target Specificity

No target annotations or specificity data are provided for SC-67655.

  • Antigen/Target: Not specified for this item; refer to CoA/Spec Sheet.
  • Species reactivity, isotype/clone: Not applicable; this is a small-molecule listing.

If activity is identified in your assays, confirm specificity by:

  • Orthogonal assay formats (biochemical vs. biophysical vs. cellular)
  • Counter-screens against related targets
  • Assessing off-target panels when feasible

All target-related claims should be based on your generated data; none are provided here.

Hai bisogno di aiuto per scegliere la qualità?

La nostra guida alla selezione delle qualità copre purezza, stato dello stabilizzatore e idoneità all'applicazione per tutte le varianti del nostro catalogo.

Visualizza la guida alle qualità Moligand™ →

Desidera che le inviamo un messaggio quando avremo sconti disponibili?

Ricordamelo più tardi

Grazie! Controlli la sua casella di posta per confermare.

Ops! Le notifiche sono disabilitate.